Screening for Cervical Cancer

Journal of Obstetrics and Gynaecology Canada

Volumn 29, Issue 8, 2007, Pages S27-S36

  Murphy, K Joan ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ALGORITHM; ARTICLE; BIOTECHNOLOGY; CANADA; CANCER SCREENING; COLPOSCOPY; COMPARATIVE STUDY; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS DNA TEST; HYSTERECTOMY; PAPILLOMAVIRUS INFECTION; PREGNANCY; PROTOCOL COMPLIANCE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; YOUNG ADULT;

EID: 84975732667     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)32578-6     Document Type: Article

References (46)

1. Walton R.J., Blanchet M., Boyes D.A., Carmichael J., Marshall K.G., Miller A.B., et al. Cervical cancer screening programs. Can Med Assoc J 1976, 114:1003-1033.
2. Canadian Task Force on Cervical Screening Programs Cervical cancer screening programs: summary of the 1982 Task Force report. Can Med Assoc J 1982, 127.
3. Miller A.B., Anderson G., Brisson J., Laidlaw J., Le Pitre N., Malcolmson P., et al. Report of a national workshop on screening for cancer of the cervix. Can Med Assoc J 1991, 145:1301-1325.
4. Parboosingh E.J., Anderson G., Clarke E.A., Inhaber S., Kaegi E., Mills C., et al. Cervical cancer screening: Are the 1989 recommendations still valid? National Workshop on Screening for Cancer of the Cervix. Can Med Assoc J 1996, 154:1847-1853.
5. Canada Health Cervical cancer screening in Canada: 1998 surveillance report 2002, Minister of Public Works and Government Services Canada, Ottawa.
6. Laara E., Day N.E., Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987, 1:1247-1249.
7. BC Cancer Agency. Cervical Cancer Screening Program, 2005 Annual Report. Available at . Accessed 2006 Sept 5. http://www.bccancer.bc.ca/PPI/Screening/Cervical/2004+CCSP+Annual+Report.htm.
8. Alberta Cervical Cancer Screening Program. Alberta Clinical Practice Guideline for Cervical Cancer Screening, 2006 Update. Available at . Accessed 2006 Sept 5. http://www.cancerboard.ab.ca/accsp/resources.html.
9. Saskatchewan Cancer Agency. Prevention Program for Cervical Cancer. Available at . Accessed 2006 Sept 5. http://www.scf.sk.ca/PPCC/PPCC_web/Prevention%20Program%20For%20Cervical%20Cancer%20Frame.htm.
10. Manitoba Cancer Care. Manitoba Cervical Cancer Screening Program, the Fundamentals, September 2000. Available at . Accessed 2006 Sept 5. http://www.cancercare.mb.ca/MCCSP/index.shtml.
11. Cancer Care Ontario: Ontario Cervical Screening Program Report 1997-2000. Available at . Accessed 2006 Sept 5. http://www.cancercare.on.ca/documents/Report97-2000Eng.pdf.
12. Cancer Care Nova Scotia Pap Test Information, Office Manual for Health Professionals, Quick Reference Card Available at, Accessed 2006 Sept 5. http://www.cancercare.ns.ca/inside.asp?cmPageID=323.
13. PEI Pap Screening Program Report Available at, Accessed 2006 Sept 5. http://www.gov.pe.ca/infopei/index.php3?number=62340&lang=E.
14. Johnson K. Periodic health examination, 1995 update: 1. Screening for human papillomavirus infection in asymptomatic women. Canadian Task Force on the Periodic Health Examination. CMAJ 1995, 152(4):483-493. Available at, Accessed 2006 Sept 5. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=7859196.
15. Hankins C., Coutlée F., Lapointe N., Simard P., Tran T., Samson J., et al. Canadian Women's HIV Study Group. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. CMAJ 1999, 160:185-191.
16. Spitzer M. Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Obstet Gynecol Surv 1999, 54:131-137.
17. Moscicki A.B. Impact of HPV infection in adolescent populations. J Adolesc Health 2005, 37(Suppl):S3-S9.
18. ACOG Committee Opinion: Evaluation and management of abnormal cervical cytology and histology in the adolescent. Obstet Gynecol 2006, 107:963-968.
19. American Society for Colposcopy and Cervical Pathology Consensus guidelines for the management of women with cytological abnormalities. JAMA 2002, 287:2120-2129. http://www.asccp.org/pdfs/consensus/algorithms.pdf. Accessed 2007 May 30.
20. Nieminen P., Kallio M., Anttila A., Hakama M. Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer 1999, 83:55-58.
21. IARC Working Group on the Evaluation of Cancer-Preventive Strategies. Evaluation. Cervix cancer screening [IARC handbooks of cancer prevention 10] 2005, International Agency for Research on Cancer, Lyon, France.
22. Quinn M., Babb P., Jones J., Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999, 318:904-908.
23. Peto J., Gilham C., Deacon J., Taylor C., Evans C., Binns W., et al. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004, 364:249-256.
24. Benedet J.L., Anderson G.H., Matisic J.P. A comprehensive program for cervical cancer detection and management. Am J Obstet Gynecol 1992, 166:1254-1259.
25. Sigurdsson K. Effect of organized screening on the risk of cervical cancer: evaluation of screening in Iceland. Int J Cancer 1993, 54:563-570.
26. Fahey M.T., Irwig L., Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995, 141:680-689.
27. Nanda K., McCrory D.C., Myers E.R., Bastian L.A., Hasselblad V., Hickey J.D., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000, 132:810-819.
28. Sawaya G.F., Sung H.Y., Kearney K.A., Miller M., Kinney W., Hiatt R.A., et al. Current approaches to cervical-cancer screening. NEngl J Med 2001, 344:1603-1607.
29. Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., Smith R.A., Eyre H.J., et al. American Cancer Society. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. Cancer J Clin 2002, 52:342-362.
30. Maxwell C.J., Bancej C.M., Snider J., Vik S.A. Factors important in promoting cervical cancer screening among Canadian women: findings from the 1996-97 National Population Health Survey (NPHS). Can J Public Health 2001, 92:127-133.
31. Mayeaux E.J., Harper M.B., Abreo F., Pope J.B., Phillips G.S. A comparison of the reliability of repeat cervical smears and colposcopy in patients with abnormal cervical cytology. J Fam Pract 1995, 40:57-62.
32. Colgan T.J., Clarke A., Hakh N., Seidenfeld A. Screening for cervical disease in mature women: strategies for improvement. Cancer 2002, 96:195-203.
33. Monsonego J., Autillo-Touati A., Bergeron C., Dachez R., Liaras J., Saurel J., et al. Liquid-based cytology for primary cervical cancer screening: a multi-centre study. Br J Cancer 2001, 84:360-366.
34. McNeeley S.G. New cervical cancer screening techniques. Am J Obstet Gynecol 2003, 189(Suppl):S40-S41.
35. Sarfati D., Cox B., Jones R.W., Sopoaga T., Rimene C., Paul C. National audit of women with abnormal cervical smears in New Zealand. Aust N Z J Obstet Gynecol 2003, 43:152-156.
36. Peterson N.B., Han J., Freund K.M. Inadequate follow-up for abnormal Pap smears in an urban population. J Natl Med Assoc 2003, 95:825-832.
37. Gage J.C., Ferreccio C., Gonzales M., Arroyo R., Huivin M., Robles S.C. Follow-up care of women with an abnormal cytology in a low-resource setting. Cancer Detect Prev 2003, 27:466-471.
38. Solomon D. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119.
39. Henry M.R. The Bethesda System 2001: an update of new terminology for gynecologic cytology. Clin Lab Med 2003, 23:585-603.
40. The 1988 Bethesda System for Reporting Cervical/Vaginal Cytological Diagnosis National Cancer Institute Workshop. JAMA 1989, 262:931-934.
41. Franco E.L., Duarte-Franco E., Ferenczy A. Prospects for controlling cervical cancer at the turn of the century. Salud Publica Mex 2003, 45(Suppl 3):S367-S375.
42. National Institute for Health and Clinical Excellence Cervical cancer-cervical screening (review): Liquid-based cytology for cervical screening (review). Technology appraisal TA69 Available at, Accessed 2007 May 30. http://guidance.nice.org.uk/TA69.
43. Colgan T.J. Programmatic assessments of the clinical effectiveness of gynecologic liquid-based cytology. Cancer 2003, 99:259-262.
44. Villa L.L., Costa R.L.R., Petta C.A. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV types 6/11/16/18) L1 virus-like particle (VLP) vaccine through up to 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.
45. National Advisory Committee on Immunization Statement on human papillomavirus vaccine. Can Commun Dis Rep 2007, 33(ACS-2):24.
46. Garnett G.P., Kim J.J., French K., Goldie S.J. Modeling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006, 24(Suppl 3):178-186.